Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial
José Baselga(Memorial Sloan Kettering Cancer Center), Seock‐Ah Im(Seoul National University Hospital), Hiroji Iwata(Aichi Cancer Center), Javier Cortés(Instituto Cajal), Michele De Laurentiis(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Zefei Jiang(307th Hospital of Chinese People’s Liberation Army), Carlos L. Arteaga(Vanderbilt University), W. Jonat(University Hospital Schleswig-Holstein), Mark Clemons(Ottawa Hospital), Yoshinori Ito(Japanese Foundation For Cancer Research), Ahmad Awada(Université Libre de Bruxelles), Stephen Chia(BC Cancer Agency), Agnieszka Jagiełło-Gruszfeld(The Maria Sklodowska-Curie National Research Institute of Oncology), Barbara Pistilli(Ospedale di Macerata), Ling‐Ming Tseng(National Yang Ming Chiao Tung University), Sara A. Hurvitz(University of California, Los Angeles), Norikazu Masuda(Osaka National Hospital), Masato Takahashi(National Hospital Organization Hokkaido Medical Center), Peter Vuylsteke(UCLouvain), Soulef Hachemi(Novartis (France)), Bharani Dharan(Novartis (United States)), Emmanuelle di Tomaso, Patrick Urban(Novartis (Switzerland)), Cristian Massacesi(Novartis (France)), Mario Campone(Institut de Cancérologie de l'Ouest)
Cited by 539Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis